Søgeresultater - Noriko Yanagitani
- Showing 1 - 20 results of 21
- Go to Next Page
-
1
-
2
-
3
Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regi... af Mayu Sugai, Yoshiaki Amino, Seitaro Fujishima, Kyujiro Nibuya, Hirokazu Iso, Masahiro Ito, Ryosuke Tsugitomi, Ryo Ariyasu, Ken Uchibori, Noriko Yanagitani, Makoto Nishio
Udgivet 2025Artigo -
4
Prognostic significance of L‐type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung af Kyoichi Kaira, Noboru Oriuchi, Hisao Imai, Kimihiro Shimizu, Noriko Yanagitani, Noriaki Sunaga, Takeshi Hisada, Tamotsu Ishizuka, Yoshikatsu Kanai, Hitoshi Endou, Takashi Nakajima, Masatomo Mori
Udgivet 2008Artigo -
5
Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer af Kyoichi Kaira, Noboru Oriuchi, Hisao Imai, Kimihiro Shimizu, Noriko Yanagitani, Noriaki Sunaga, Takeshi Hisada, Shigebumi Tanaka, Tamotsu Ishizuka, Yoshikatsu Kanai, Hitoshi Endou, Takahiro Nakajima, Masatomo Mori
Udgivet 2008Artigo -
6
<scp>l</scp>‐type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms af Kyoichi Kaira, Noboru Oriuchi, Hisao Imai, Kimihiro Shimizu, Noriko Yanagitani, Noriaki Sunaga, Takeshi Hisada, Shigebumi Tanaka, Tamotsu Ishizuka, Yoshikatsu Kanai, Hitoshi Endou, Takashi Nakajima, Masatomo Mori
Udgivet 2008Artigo -
7
Detection of epidermal growth factor receptor T790M mutation in plasma <scp>DNA</scp> from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor af Kazuko Sakai, Atsushi Horiike, Darryl Irwin, Keita Kudo, Yoshihiko Fujita, Azusa Tanimoto, Toshio Sakatani, Ryota Saito, Kyohei Kaburaki, Noriko Yanagitani, Fumiyoshi Ohyanagi, Makoto Nishio, Kazuto Nishio
Udgivet 2013Artigo -
8
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms af Noriko Yanagitani, Ken Uchibori, Sumie Koike, Mika Tsukahara, Satoru Kitazono, Takahiro Yoshizawa, Atsushi Horiike, Fumiyoshi Ohyanagi, Yuichi Tambo, Shingo Nishikawa, Naoya Fujita, Ryohei Katayama, Makoto Nishio
Udgivet 2020Artigo -
9
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer af Bo Gong, Kazuma Kiyotani, Seiji Sakata, Seiji Nagano, Shun Kumehara, Satoko Baba, Benjamin Besse, Noriko Yanagitani, Luc Friboulet, Makoto Nishio, Kengo Takeuchi, Hiroshi Kawamoto, Naoya Fujita, Ryohei Katayama
Udgivet 2019Artigo -
10
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand... af Takehiro Tozuka, Satoru Kitazono, Hiroaki Sakamoto, Hiroshi Yoshida, Yoshiaki Amino, Shinya Uematsu, Takahiro Yoshizawa, Tsukasa Hasegawa, Ken Uchibori, Noriko Yanagitani, Atsushi Horiike, Takeshi Horai, Masahiro Seike, Akihiko Gemma, Makoto Nishio
Udgivet 2020Artigo -
11
Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results fro... af David Planchard, Po‐Hao Feng, Nina Karaseva, S.-W. Kim, T.M. Kim, Chee Khoon Lee, Artem Poltoratskiy, Noriko Yanagitani, Ryan Marshall, X. Huang, Paul Howarth, Pasi A. Jänne, Kunihiko Kobayashi
Udgivet 2021Artigo -
12
Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy af Noriaki Sunaga, David S. Shames, Luc Girard, Michael Peyton, Jill E. Larsen, Hisao Imai, Junichi Soh, Mitsuo Sato, Noriko Yanagitani, Kyoichi Kaira, Yang Xie, Adi F. Gazdar, Masatomo Mori, John D. Minna
Udgivet 2011Artigo -
13
Association of amino acid substitution polymorphisms in DNA repair genes <i>TP53</i>, <i>POLI</i>, <i>REV1</i> and <i>LIG4</i> with lung cancer risk af Tokuki Sakiyama, Takashi Kohno, Sachiyo Mimaki, Tsutomu Ohta, Noriko Yanagitani, Tomotaka Sobue, Hideo Kunitoh, Ryusei Saito, Kimiko Shimizu, Chie Hirama, Junko Kimura, Go Maeno, Hiroshi Hirose, Takashi Eguchi, Daizo Saito, Misao Ohki, Jun Yokota
Udgivet 2004Artigo -
14
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations af Satoshi Morita, Isamu Okamoto, Kunihiko Kobayashi, Koichi Yamazaki, Hajime Asahina, Akira Inoue, Koichi Hagiwara, Noriaki Sunaga, Noriko Yanagitani, Toyoaki Hida, Kimihide Yoshida, Tomonori Hirashima, Kosei Yasumoto, Kenji Sugio, Tetsuya Mitsudomi, Masahiro Fukuoka, Toshihiro Nukiwa
Udgivet 2009Revisão -
15
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance af Koutaroh Okada, Mitsugu Araki, Takuya Sakashita, Biao Ma, Ryo Kanada, Noriko Yanagitani, Atsushi Horiike, Sumie Koike, Tomoko Oh‐hara, Kana Watanabe, Keiichi Tamai, Makoto Maemondo, Makoto Nishio, Takeshi Ishikawa, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
Udgivet 2019Artigo -
16
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation af Ray Sagawa, Seiji Sakata, Bo Gong, Yosuke Seto, Ai Takemoto, Satoshi Takagi, Hironori Ninomiya, Noriko Yanagitani, Masayuki Nakao, Mingyon Mun, Ken Uchibori, Makoto Nishio, Yasunari Miyazaki, Yuichi Shiraishi, Seishi Ogawa, Keisuke Kataoka, Naoya Fujita, Kengo Takeuchi, Ryohei Katayama
Udgivet 2021Artigo -
17
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of <i>ALK</i> Mutation Status af Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nishiyama, Takayuki Nakagawa, Hirokazu Taniguchi, Takeshi Suzuki, Tadaaki Yamada, Hiroshi Nishihara, Hironori Ninomiya, Yuichi Ishikawa, Satoko Baba, Kengo Takeuchi, Atsushi Horiike, Noriko Yanagitani, Makoto Nishio, Seiji Yano
Udgivet 2019Artigo -
18
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer af Ryohei Katayama, Takuya Sakashita, Noriko Yanagitani, Hironori Ninomiya, Atsushi Horiike, Luc Friboulet, Justin F. Gainor, Noriko Motoi, Akito Dobashi, Seiji Sakata, Yuichi Tambo, Satoru Kitazono, Shigeo Sato, Sumie Koike, A. John Iafrate, Mari Mino‐Kenudson, Yuichi Ishikawa, Alice T. Shaw, Jeffrey A. Engelman, Kengo Takeuchi, Makoto Nishio, Naoya Fujita
Udgivet 2015Artigo -
19
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models af Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima, Yuki Shimizu, Yosuke Seto, Tomoko Oh‐hara, Sumie Koike, Naoki Nakao, Hiroyuki Hanzawa, Kengo Watanabe, Satoshi Yoda, Noriko Yanagitani, Aaron N. Hata, Alice T. Shaw, Makoto Nishio, Naoya Fujita, Takeshi Isoyama
Udgivet 2019Artigo -
20
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer af Hayato Mizuta, Koutaroh Okada, Mitsugu Araki, Jun Adachi, Ai Takemoto, Justyna Kutkowska, Kohei Maruyama, Noriko Yanagitani, Tomoko Oh‐hara, Kana Watanabe, Keiichi Tamai, Luc Friboulet, Kazuhiro Katayama, Biao Ma, Yoko Sasakura, Yukari Sagae, Mutsuko Kukimoto‐Niino, Mikako Shirouzu, Satoshi Takagi, Siro Simizu, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
Udgivet 2021Artigo
Søgeredskaber:
Relaterede emner
Medicine
Internal medicine
Lung cancer
Biology
Cancer
Cancer research
Oncology
Genetics
Gene
Crizotinib
Malignant pleural effusion
ALK inhibitor
Mutation
Alectinib
Anaplastic lymphoma kinase
Ceritinib
Epidermal growth factor receptor
Pathology
Receptor
Gastroenterology
Immune checkpoint
Immune system
Immunohistochemistry
Immunology
Immunotherapy
Acquired resistance
Adenocarcinoma
Adverse effect
Angiogenesis
Antibody